关注
Alexander Schuhmacher
Alexander Schuhmacher
未知所在单位机构
在 thi.de 的电子邮件经过验证
标题
引用次数
引用次数
年份
Changing R&D models in research-based pharmaceutical companies
A Schuhmacher, O Gassmann, M Hinder
Journal of translational medicine 14, 1-11, 2016
3952016
Models for open innovation in the pharmaceutical industry
A Schuhmacher, PG Germann, H Trill, O Gassmann
Drug discovery today 18 (23-24), 1133-1137, 2013
2022013
Translational precision medicine: an industry perspective
D Hartl, V de Luca, A Kostikova, J Laramie, S Kennedy, E Ferrero, ...
Journal of translational medicine 19 (1), 245, 2021
952021
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
A Schuhmacher, O Gassmann, N McCracken, M Hinder
Journal of translational medicine 16, 1-14, 2018
822018
The upside of being a digital pharma player
A Schuhmacher, A Gatto, M Hinder, M Kuss, O Gassmann
Drug discovery today 25 (9), 1569-1574, 2020
562020
Identification and characterization of secreted effector proteins of Chlamydophila pneumoniae TW183
M Herrmann, A Schuhmacher, I Mühldorfer, K Melchers, C Prothmann, ...
Research in microbiology 157 (6), 513-524, 2006
492006
R&D efficiency of leading pharmaceutical companies–A 20-year analysis
A Schuhmacher, L Wilisch, M Kuss, A Kandelbauer, M Hinder, ...
Drug discovery today 26 (8), 1784-1789, 2021
482021
Properties and function of the P type ion pumps cloned from Helicobacter pylori.
K Melchers, L Herrmann, F Mauch, D Bayle, D Heuermann, ...
Acta physiologica scandinavica. Supplementum 643, 123-135, 1998
471998
Membrane topology of CadA homologous P-type ATPase of Helicobacter pylori as determined by expression of phoA fusions in Escherichia coli and the positive inside rule
K Melchers, A Schuhmacher, A Buhmann, T Weitzenegger, D Belin, ...
Research in microbiology 150 (8), 507-520, 1999
341999
Open innovation: A paradigm shift in pharma R&D?
A Schuhmacher, O Gassmann, D Bieniok, M Hinder, D Hartl
Drug Discovery Today 27 (9), 2395-2405, 2022
282022
Value creation in the pharmaceutical industry: the critical path to innovation
A Schuhmacher, M Hinder, O Gassmann
John Wiley & Sons, 2016
262016
Big Techs and startups in pharmaceutical R&D–A 2020 perspective on artificial intelligence
A Schuhmacher, A Gatto, M Kuss, O Gassmann, M Hinder
Drug Discovery Today 26 (10), 2226-2231, 2021
242021
Analysis of pharma R&D productivity–a new perspective needed
A Schuhmacher, M Hinder, AS und Stein, D Hartl, O Gassmann
Drug Discovery Today, 103726, 2023
222023
Leading pharmaceutical innovation: How to win the life science race
O Gassmann, A Schuhmacher, M Von Zedtwitz, G Reepmeyer
Springer, 2018
222018
Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D in vitro testing model
M Behbehani, A Glen, CS Taylor, A Schuhmacher, F Claeyssens, ...
International journal of bioprinting 4 (1), 2018
192018
How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective
PG Germann, A Schuhmacher, J Harrison, R Law, K Haug, G Wong
Human genomics 7, 1-6, 2013
162013
The art of virtualizing pharma R&D
A Schuhmacher, O Gassmann, M Kuss, M Hinder
Drug Discovery Today 24, 2105-2107, 2019
152019
A review of the pharmaceutical R&D efficiency: costs, timelines, and probabilities
A Schuhmacher, O Gassmann, M Hinder
Value creation in the pharmaceutical industry: the critical path to …, 2016
152016
The significance of blockbusters in the pharmaceutical industry.
A Schuhmacher, M Hinder, N Boger, D Hartl, O Gassmann
drugs 62, 37, 2022
132022
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
A Schuhmacher, C Brieke, O Gassmann, M Hinder, D Hartl
Drug discovery today 26 (12), 2786-2793, 2021
132021
系统目前无法执行此操作,请稍后再试。
文章 1–20